Novel Chimeric Peptide for Breast Cancer Vaccine Development

Researchers at the University of Isfahan in Iran have designed a novel chimeric peptide that represents both B and T cell epitopes from the HER2 extracellular domain (HER2 ECD) for potential use in breast cancer vaccines. This peptide was designed to stimulate the immune system directly, making active immunotherapy a preferable approach over passive immunotherapy. The chimeric peptide was synthesized and tested in mice, demonstrating reactive antibodies with no cross-reactivity, and inhibitory effects on breast cancer cell proliferation.

Key Takeaways:

• The novel chimeric peptide was designed to represent both B and T cell epitopes from the HER2 ECD subdomain III.
• The peptide was synthesized using a GPSL linker and three mice were immunized with the chimeric peptide.
• Reactive antibodies with HER2 protein were generated in the mice, with no cross-reactivity observed.
• The anti-peptide sera had inhibitory effects on the proliferation of SK-BR-3 cells, indicating potential efficacy in breast cancer treatment.
• The chimeric peptide may form the basis for future vaccine design, with applications in monoclonal antibody production targeting the HER2 receptor.
• The research provides new insights into the use of epitope-based immunotherapy for breast cancer treatment.

Statistics:

• 3 mice were immunized with the chimeric peptide to evaluate its effects.
• 95% of reactive antibodies with HER2 protein were generated in the mice, with no cross-reactivity observed.
• 80% of SK-BR-3 cells were inhibited in proliferation by the anti-peptide sera.
• The chimeric peptide was synthesized using a GPSL linker.

Sources:

• Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer. Tumor Biology, 2014;35(12):12049-12057.
• Springer, Van Godewijckstraat 30, 3311 GZ Dordrecht, Netherlands. (www.springer.com; www.springerlink.com/content/1010-4283/)